Canopy Growth Full Year 2025 Earnings: Misses Expectations

Canopy Growth (TSE:WEED) Full Year 2025 Results

Key Financial Results

• Revenue: CA$269.0m (down 9.5% from FY 2024).
• Net loss: CA$604.1m (loss widened by 25% from FY 2024).
• CA$5.62 loss per share.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Canopy Growth Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 27%.

Looking ahead, revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Canada.

Performance of the Canadian Pharmaceuticals industry.

The company's shares are down 28% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Canopy Growth (at least 2 which are potentially serious), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.